OncoMatch/Clinical Trials/NCT06935162
Teclistamab in Previously Treated AL Amyloidosis
Is NCT06935162 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Teclistamab (Tec) for al amyloidosis.
Treatment: Teclistamab (Tec) — This is a phase II study in patients with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: (daratumumab, bortezomib)
Patients must have received at least one line of treatment, including daratumumab and bortezomib; Relapse from previous treatment, or less than partial response after two cycles of treatment/less than very good partial response after three cycles of treatment
Cannot have received: anti-BCMA targeted therapy
Previous anti-BCMA targeted therapy
Lab requirements
Blood counts
Neutrophil <1×10E9/L, hemoglobin < 8g/dL, or platelet < 75×10E9/L
Kidney function
eGFR < 20 mL/min, or receiving renal replacement therapy
Liver function
ALT or AST > 5 × ULN, total bilirubin > 2 × ULN
Cardiac function
grade 2 Mobitz II or grade 3 atrioventricular block (except for those with implanted pacemaker); sustained or recurrent nonsustained ventricular tachycardia
Neutrophil <1×10E9/L, hemoglobin < 8g/dL, or platelet < 75×10E9/L. Severely compromised hepatic or renal function: ALT or AST > 5 × ULN, total bilirubin > 2 × ULN, eGFR < 20 mL/min, or receiving renal replacement therapy. Grade 2 Mobitz II or grade 3 atrioventricular block (except for those with implanted pacemaker); sustained or recurrent nonsustained ventricular tachycardia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify